This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ruers, T.J.M. Articles by Oyen, W. J.G. Search for Related Content PubMed PubMed Citation Articles by Ruers, T.J.M. Articles by Oyen, W. J.G. Social Bookmarking                            What's this?

Value of Positron Emission Tomography With [F-18]Fluorodeoxyglucose in Patients With Colorectal Liver Metastases: A Prospective Study

From the Departments of Surgery, Nuclear Medicine, and Radiology, University Medical Center Nijmegen, Nijmegen, the Netherlands.

Address reprint requests to T.J.M. Ruers, MD, Department of Surgery, University Medical Center Nijmegen, PO Box 9101, 6500 HB Nijmegen, the Netherlands; email: t.ruers{at}heel.azn.nl

PURPOSE: To assess prospectively the value of fluor-18-deoxyglucose (FDG) positron emission tomography (PET), in addition to conventional diagnostic methods (CDM), as a staging modality in candidates for resection of colorectal liver metastases.

PATIENTS AND METHODS: In 51 patients analyzed for resection of colorectal liver metastases, clinical management decisions were recorded after a complete work-up with CDM. Afterward, FDG-PET scans were performed and any change of clinical management according to FDG-PET results was carefully documented. Discordances between FDG-PET and CDM results were identified and related to the final diagnosis by histopathology, intraoperative findings, and follow-up.

RESULTS: In 10 (20%) out of 51 patients, clinical management decisions based on CDM were changed after FDG-PET findings were known. FDG-PET detected unresectable pulmonary (n = 5) and hepatic metastases (n = 1) and ruled out extrahepatic (n = 2) and hepatic disease (n = 2). Due to FDG-PET, eight patients were spared unwarranted liver resection or laparotomy and two other patients were identified as candidates for liver resection. When the results of FDG-PET were regarded as decisive in a retrospective analysis, potential change of management was 29% (15 patients). FDG-PET and CDM showed discordant extrahepatic results in 11 patients (22%) and discordant hepatic results in eight patients (16%). Compared with CDM, FDG-PET resulted in true upstaging (n = 11), true downstaging (n = 5), false upstaging (n = 1), and false downstaging (n = 2). The detection rate of liver metastases on a lesion basis was generally better for computed tomography than for FDG-PET (80% v 65%); this was related to tumor size.

CONCLUSION: FDG-PET as a complementary staging method improves the therapeutic management of patients with colorectal liver metastases, especially by detecting unsuspected extrahepatic disease.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. MONTEIL, N. MAHMOUDI, S. LEOBON, P.Y. ROUDAUT, A. EL BADAOUI, S. VERBEKE, L. VENAT-BOUVET, J. MARTIN, V. LE BRUN-LY, S. LAVAU-DENES, et al. Chemotherapy Response Evaluation in Metastatic Colorectal Cancer with FDG PET/CT and CT Scans Anticancer Res, July 1, 2009; 29(7): 2563 - 2568. [Abstract] [Full Text] [PDF]

				P. Bystrom, A. Berglund, U. Garske, H. Jacobsson, A. Sundin, P. Nygren, J.-E. Frodin, and B. Glimelius Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer Ann. Onc., June 1, 2009; 20(6): 1057 - 1061. [Abstract] [Full Text] [PDF]

				A. M. Scott, D. H. Gunawardana, B. Kelley, J. G. Stuckey, A. J. Byrne, J. E. Ramshaw, and M. J. Fulham PET Changes Management and Improves Prognostic Stratification in Patients with Recurrent Colorectal Cancer: Results of a Multicenter Prospective Study J. Nucl. Med., September 1, 2008; 49(9): 1451 - 1457. [Abstract] [Full Text] [PDF]

				L.F. de Geus-Oei, H. W. M. van Laarhoven, E. P. Visser, R. Hermsen, B. A. van Hoorn, Y. J. L. Kamm, P. F. M. Krabbe, F. H. M. Corstens, C. J. A. Punt, and W. J. G. Oyen Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer Ann. Onc., February 1, 2008; 19(2): 348 - 352. [Abstract] [Full Text] [PDF]

				R. A. Herbertson, S. T. Lee, N. Tebbutt, and A. M. Scott The expanding role of PET technology in the management of patients with colorectal cancer Ann. Onc., November 1, 2007; 18(11): 1774 - 1781. [Abstract] [Full Text] [PDF]

				F. H. Miller, A. L. Keppke, D. Reddy, J. Huang, J. Jin, M. F. Mulcahy, and R. Salem Response of Liver Metastases After Treatment with Yttrium-90 Microspheres: Role of Size, Necrosis, and PET Am. J. Roentgenol., March 1, 2007; 188(3): 776 - 783. [Abstract] [Full Text] [PDF]

				H. Kuehl, P. Veit, S. J. Rosenbaum, A. Bockisch, and G. Antoch Can PET/CT Replace Separate Diagnostic CT for Cancer Imaging? Optimizing CT Protocols for Imaging Cancers of the Chest and Abdomen J. Nucl. Med., January 1, 2007; 48(1_suppl): 45S - 57S. [Abstract] [Full Text] [PDF]

				D. L. Joyce, R. L. Wahl, P. V. Patel, R. D. Schulick, S. L. Gearhart, and M. A. Choti Preoperative Positron Emission Tomography to Evaluate Potentially Resectable Hepatic Colorectal Metastases Arch Surg, December 1, 2006; 141(12): 1220 - 1226. [Abstract] [Full Text] [PDF]

				L. de Geus-Oei, B Wiering, P. Krabbe, T. Ruers, C. Punt, and W. Oyen FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma Ann. Onc., November 1, 2006; 17(11): 1650 - 1655. [Abstract] [Full Text] [PDF]

				H Furukawa, H Ikuma, A Seki, K Yokoe, S Yuen, T Aramaki, and S Yamagushi Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer Gut, July 1, 2006; 55(7): 1007 - 1011. [Abstract] [Full Text] [PDF]

				G. K. von Schulthess, H. C. Steinert, and T. F. Hany Integrated PET/CT: Current Applications and Future Directions Radiology, February 1, 2006; 238(2): 405 - 422. [Abstract] [Full Text] [PDF]

				C. Lejeune, M. J. Bismuth, T. Conroy, C. Zanni, P. Bey, L. Bedenne, J. Faivre, P. Arveux, and F. Guillemin Use of a Decision Analysis Model to Assess the Cost-Effectiveness of 18F-FDG PET in the Management of Metachronous Liver Metastases of Colorectal Cancer J. Nucl. Med., December 1, 2005; 46(12): 2020 - 2028. [Abstract] [Full Text] [PDF]

				H. W. M. van Laarhoven, L.-F. de Geus-Oei, B. Wiering, J. Lok, M. Rijpkema, J. H. A. M. Kaanders, P. F. M. Krabbe, T. Ruers, C. J. A. Punt, A. J. van der Kogel, et al. Gadopentetate Dimeglumine and FDG Uptake in Liver Metastases of Colorectal Carcinoma as Determined with MR Imaging and PET Radiology, October 1, 2005; 237(1): 181 - 188. [Abstract] [Full Text] [PDF]

				S. Bipat, M. S. van Leeuwen, E. F. I. Comans, M. E. J. Pijl, P. M. M. Bossuyt, A. H. Zwinderman, and J. Stoker Colorectal Liver Metastases: CT, MR Imaging, and PET for Diagnosis--Meta-analysis Radiology, October 1, 2005; 237(1): 123 - 131. [Abstract] [Full Text] [PDF]

				D. V. Sahani, S. P. Kalva, A. J. Fischman, R. Kadavigere, M. Blake, P. F. Hahn, and S. Saini Detection of Liver Metastases from Adenocarcinoma of the Colon and Pancreas: Comparison of Mangafodipir Trisodium-Enhanced Liver MRI and Whole-Body FDG PET Am. J. Roentgenol., July 1, 2005; 185(1): 239 - 246. [Abstract] [Full Text] [PDF]

				M. C.A. van Kouwen, F. M. Nagengast, J. B.M.J. Jansen, W. J.G. Oyen, and J. P.H. Drenth 2-(18F)-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Detects Clinical Relevant Adenomas of the Colon: A Prospective Study J. Clin. Oncol., June 1, 2005; 23(16): 3713 - 3717. [Abstract] [Full Text] [PDF]

				J.-H. Kim, J. Czernin, M. S. Allen-Auerbach, B. S. Halpern, B. J. Fueger, J. R. Hecht, O. Ratib, M. E. Phelps, and W. A. Weber Comparison Between 18F-FDG PET, In-Line PET/CT, and Software Fusion for Restaging of Recurrent Colorectal Cancer J. Nucl. Med., April 1, 2005; 46(4): 587 - 595. [Abstract] [Full Text] [PDF]

				M. Torabi, S. L. Aquino, and M. G. Harisinghani Current Concepts in Lymph Node Imaging J. Nucl. Med., September 1, 2004; 45(9): 1509 - 1518. [Abstract] [Full Text] [PDF]

				I. Kantorova, L. Lipska, O. Belohlavek, V. Visokai, M. Trubac, and M. Schneiderova Routine 18F-FDG PET Preoperative Staging of Colorectal Cancer: Comparison with Conventional Staging and Its Impact on Treatment Decision Making J. Nucl. Med., November 1, 2003; 44(11): 1784 - 1788. [Abstract] [Full Text] [PDF]

				C. Cohade, M. Osman, J. Leal, and R. L. Wahl Direct Comparison of 18F-FDG PET and PET/CT in Patients with Colorectal Carcinoma J. Nucl. Med., November 1, 2003; 44(11): 1797 - 1803. [Abstract] [Full Text] [PDF]

				B B Chin and R L Wahl 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies Gut, June 1, 2003; 52(90004): iv23 - 29. [Abstract] [Full Text] [PDF]

				L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith Clinical Role of FDG PET in Evaluation of Cancer Patients RadioGraphics, March 1, 2003; 23(2): 315 - 340. [Abstract] [Full Text] [PDF]

				L. Kostakoglu and S. J. Goldsmith 18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma J. Nucl. Med., February 1, 2003; 44(2): 224 - 239. [Abstract] [Full Text] [PDF]

				B. G.M. Durie, A. D. Waxman, A. D'Agnolo, and C. M. Williams Whole-Body 18F-FDG PET Identifies High-Risk Myeloma J. Nucl. Med., November 1, 2002; 43(11): 1457 - 1463. [Abstract] [Full Text] [PDF]